北京美科美生物公司代理Pluristyx

hPSC
hiPSC
Custom iPSC
Differentiated Cells

Pluristyx成立于2018年，是一家先进的治疗工具公司，旨在帮助公司和研究人员解决药物开发、再生医学以及细胞和基因治疗领域的制造挑战。Pluristyx通过提供CMC咨询、合同开发服务以及研究和临床级即用（RTU）服务，提供无缝的客户支持™) 并准备好与众不同（RTD）™) 商业规模的多能干细胞。通过这样做，Pluristyx有效地将扩张和银行业务的麻烦与差异化和产品开发分离开来，使早期公司能够将宝贵的资源集中在治疗应用上，而不是制造障碍，最终目标是将有希望的实验室发现推进到患者身上。

Pluristyx was established in 2018 as an advanced therapy tools company to help companies and researchers solve manufacturing challenges in the field of drug development, regenerative medicine, and cell and gene therapy. Pluristyx provides seamless client support by offering CMC consulting, contract development services, and research- and clinical-grade Ready-to-Use (RTU™) and Ready-To-Differentiate (RTD™) Pluripotent Stem Cells at a commercial scale. In doing so, Pluristyx effectively decouples the hassles of expansion and banking from differentiation and product development, allowing early-stage companies to focus precious resources on therapeutic application rather than manufacturing hurdles, with the ultimate goal of advancing promising laboratory discoveries into patients.